Abstract: The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.

Abstract: The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.

Abstract: Systems and methods for analyzing a sample comprising an analyte selected from a volatile organic compound, a semi-volatile organic compound, a non-volatile organic compound, a polar organic compound and a halogenated non-volatile organic compound are provided. The systems comprises an ionization source, a flow cell or an immersion probe with a delicate membrane, the flow cell or immersion probe for accepting the sample, and the delicate membrane interface in fluid communication with the ionization source and a mass spectrometer. The flow cell system further comprises a simultaneously matched pumping in and out delivery (SMPIOD) system for delivering an acceptor phase comprising the analyte from the delicate membrane interface to the mass spectrometer at a constant acceptor flow pressure and a constant acceptor flow rate.

Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

Abstract: Systems and methods for analyzing a sample comprising an analyte selected from a volatile organic compound, a semi-volatile organic compound, a non-volatile organic compound, a polar organic compound and a halogenated non-volatile organic compound are provided. The systems comprises an ionization source, a flow cell or an immersion probe with a delicate membrane, the flow cell or immersion probe for accepting the sample, and the delicate membrane interface in fluid communication with the ionization source and a mass spectrometer. The flow cell system further comprises a simultaneously matched pumping in and out delivery (SMPIOD) system for delivering an acceptor phase comprising the analyte from the delicate membrane interface to the mass spectrometer at a constant acceptor flow pressure and a constant acceptor flow rate.

Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

Abstract: A membrane introduction mass spectrometry (MIMS) sampling interface is presented that demonstrates improved online performance for the direct, real-time measurement of semi-volatile organic compounds (SVOCs) in samples such as air and water, at parts-per-billion and parts-per-trillion levels. The device is based upon a capillary hollow fiber silicone (polydimethylsiloxane) membrane in a ‘flow-over’ configuration that is resistively heated on the membrane interior. One embodiment resistively heats using a coaxial nichrome wire, establishing a thermal gradient counter to the analyte concentration gradient. This arrangement allows for continuous and/or pulsed heating modes, affording excellent sensitivity for the online measurement of SVOCs while retaining sensitivity for volatile organic compounds (VOCs). In addition, the signal response time for SVOCs is reduced substantially over conventional MIMS methods.